{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:09:29Z","timestamp":1792202969955,"version":"4.4.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Allergology International"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.alit.2025.03.002","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T16:28:37Z","timestamp":1743956917000},"page":"380-385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacogenetic biomarkers associated with risk of developing severe drug eruptions and clinical implementation of HLA genetic testing"],"prefix":"10.1016","volume":"74","author":[{"given":"Taisei","family":"Mushiroda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.alit.2025.03.002_bib1","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13059-017-1207-1","article-title":"The MHC locus and genetic susceptibility to autoimmune and infectious diseases","volume":"18","author":"Matzaraki","year":"2017","journal-title":"Genome Biol"},{"key":"10.1016\/j.alit.2025.03.002_bib2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","article-title":"Association between presence of HLA-B\u22175701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir","volume":"359","author":"Mallal","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.alit.2025.03.002_bib3","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.alit.2025.03.002_bib4","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/hmg\/ddq537","article-title":"Genome-wide association study identifies HLA-A\u22173101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population","volume":"20","author":"Ozeki","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.alit.2025.03.002_bib5","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1001\/jamaneurol.2018.0278","article-title":"Association of HLA-A\u221731:01 screening with the incidence of carbamazepine-induced cutaneous adverse reactions in a Japanese population","volume":"5","author":"Mushiroda","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.alit.2025.03.002_bib6","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jid.2023.09.282","article-title":"Differential effects of HLA-B\u221715:11 and HLA-A\u221731:01 on carbamazepine-induced cutaneous adverse reactions","volume":"144","author":"Fukunaga","year":"2024","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.alit.2025.03.002_bib7","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.jaip.2024.02.041","article-title":"Association of HLA-A\u221711:01, HLA-B\u221739:01, and HLA-B\u221756:03 with salazosulfapyridine-induced cutaneous adverse drug reactions","volume":"12","author":"Fukunaga","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2025.03.002_bib8","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1016\/j.jid.2023.04.017","article-title":"Association of genetic variants of HLA-DQA1 with bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors","volume":"143","author":"Ozeki","year":"2023","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.alit.2025.03.002_bib9","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.jid.2017.11.023","article-title":"HLA-DQB1\u221703:01 as a biomarker for genetic susceptibility to bullous pemphigoid induced by DPP-4 inhibitors","volume":"138","author":"Ujiie","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.alit.2025.03.002_bib10","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/cpt.1190","article-title":"HLA alleles and CYP2C9\u22173 as predictors of phenytoin hypersensitivity in East Asians","volume":"105","author":"Su","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.alit.2025.03.002_bib11","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/cpt.1706","article-title":"HLA-B\u221751:01 and CYP2C9\u22173 are risk factors for phenytoin-induced eruption in the Japanese population: analysis of data from the biobank Japan project","volume":"107","author":"Hikino","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.alit.2025.03.002_bib12","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jid.2016.02.808","article-title":"Impact of the HLA-B\u221758:01 allele and renal impairment on allopurinol-induced cutaneous adverse reactions","volume":"136","author":"Ng","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.alit.2025.03.002_bib13","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B\u22175701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.alit.2025.03.002_bib14","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1056\/NEJMoa1009717","article-title":"Carbamazepine-induced toxic effects and HLA-B\u22171502 screening in Taiwan","volume":"364","author":"Chen","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.alit.2025.03.002_bib15","article-title":"Use of HLA-B\u221758:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study","volume":"351","author":"Ko","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.alit.2025.03.002_bib16","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamadermatol.2018.5360","article-title":"Evaluation of prospective HLA-B\u221713:01 screening to prevent dapsone hypersensitivity syndrome in patients with leprosy","volume":"155","author":"Liu","year":"2019","journal-title":"JAMA Dermatol"}],"container-title":["Allergology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893025000267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893025000267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T18:48:18Z","timestamp":1762368498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1323893025000267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1323893025000267"],"URL":"https:\/\/doi.org\/10.1016\/j.alit.2025.03.002","relation":{},"ISSN":["1323-8930"],"issn-type":[{"value":"1323-8930","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenetic biomarkers associated with risk of developing severe drug eruptions and clinical implementation of HLA genetic testing","name":"articletitle","label":"Article Title"},{"value":"Allergology International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.alit.2025.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society of Allergology. Published by Elsevier B.V\u00e9","name":"copyright","label":"Copyright"}]}}